Recommendations for the Management of MPS IVA: Systematic Evidence- and Consensus-Based Guidance Mehmet Umut Akyol1, Tord D
Akyol et al. Orphanet Journal of Rare Diseases (2019) 14:137 https://doi.org/10.1186/s13023-019-1074-9 RESEARCH Open Access Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance Mehmet Umut Akyol1, Tord D. Alden2, Hernan Amartino3, Jane Ashworth4, Kumar Belani5, Kenneth I. Berger6, Andrea Borgo7, Elizabeth Braunlin8, Yoshikatsu Eto9, Jeffrey I. Gold10, Andrea Jester11, Simon A. Jones12, Cengiz Karsli13, William Mackenzie14, Diane Ruschel Marinho15, Andrew McFadyen16, Jim McGill17, John J. Mitchell18, Joseph Muenzer19, Torayuki Okuyama20, Paul J. Orchard21, Bob Stevens22, Sophie Thomas22, Robert Walker23, Robert Wynn24, Roberto Giugliani25, Paul Harmatz26, Christian Hendriksz27* , Maurizio Scarpa28, MPS Consensus Programme Steering Committee and MPS Consensus Programme Co-Chairs Abstract Introduction: Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is an autosomal recessive lysosomal storage disorder (LSD) caused by deficiency of the N-acetylgalactosamine-6-sulfatase (GALNS) enzyme, which impairs lysosomal degradation of keratan sulphate and chondroitin-6-sulphate. The multiple clinical manifestations of MPS IVA present numerous challenges for management and necessitate the need for individualised treatment. Although treatment guidelines are available, the methodology used to develop this guidance has come under increased scrutiny. This programme was conducted to provide evidence-based, expert-agreed recommendations to optimise management of MPS IVA. Methods: Twenty six international healthcare
[Show full text]